Actively Recruiting
Comparing Apixaban, Rivaroxaban, and Low-Molecular-Weight Heparin for Blood Clot Prevention After Primary Total Knee Replacement Surgery Using Duplex Ultrasound
Led by Military Hospital of Tunis · Updated on 2026-10-16
138
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare three different blood clot prevention treatments in adults who are having their first total knee replacement surgery. The study focuses on how these treatments affect blood flow in the veins of the lower limbs after surgery. It also evaluates other important health factors like rehabilitation progress, bleeding, and complications such as venous thromboembolism and cardiovascular issues during the recovery period. Participants will be randomly assigned to one of three treatment groups receiving apixaban twice daily, rivaroxaban once daily, or a weight-adjusted dose of enoxaparin once daily. All participants initially receive enoxaparin six hours after surgery, followed by their assigned treatment starting 24 hours after surgery, continuing for 14 days. Blood flow will be assessed with Doppler ultrasound at baseline and on Days 7, 15, 21, and 28 after surgery, with the examiner unaware of treatment assignments. During the study, participants will undergo several evaluations including Doppler ultrasound measurements of blood flow in specific leg veins, assessments of joint movement, pain, immobilization, and any postoperative complications. The main outcome measured is the peak speed of blood flow in the common femoral vein over 28 days. Safety and recovery will be closely monitored, and the total follow-up lasts 28 days after surgery.
CONDITIONS
Brief Title
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Research Team
H
Haythem Elaskri
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here